MedTrace Logo

Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

NCT07070128 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2026-05-13

No results posted yet for this study

Summary

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-20
Primary Completion
2026-08-11
Completion
2026-08-11

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070128 on ClinicalTrials.gov